The doctors of Eyes on Sheppard are pleased to announce that Macula Risk genetic testing is now being offered for patients with Age-related Macular Degeneration (AMD).
Combined with a routine clinical eye examination, results of the Macula Risk® PGx test determine which patients are at the highest risk of vision loss from AMD, and guide our doctors in prescribing the safest, most effective eye vitamin formulations for our patients based on their genetics.
The Age-Related Eye Disease Study (AREDS) has demonstrated that eye vitamins can protect a significant percentage of patients from developing advanced AMD. Recent data suggests, however, that ingredients within the commonly prescribed AREDS formulation, specifically antioxidants and zinc, may be helpful or harmful to some patients based on their genetics.
“Knowing this information is key to prescribing the right eye vitamin formulations to our patients and to ensuring that, as eye doctors, we are doing everything we can to protect our patients from vision loss”, states Dr. Kerry Salsberg.
In addition to making personalized eye vitamin recommendations to patients, the doctors of Eyes on Sheppard are also using the information provided in the Macula Risk PGx patient report to customize disease management programs for patients based on their risk.
The Macula Risk test allows patients with a family history of age related macular degeneration to determine if they have the genetic markers of the disease. If so, it allows our doctors to better manage high-risk patients through disease education, lifestyle modifications and an increased frequency of eye examinations where necessary.
The Macula Risk PGx test is a simple, painless cheek swab, performed in our office, for patients with a diagnosis of early or intermediate AMD. Additional information about the Macula Risk PGx test is available here.